It is thought that dysregulation of the gut microbiome could cause increased production of pro-inflammatory toxins that can predispose patients to the development of UC.
An area that has been specifically challenging within gastroenterology is the management of how and when to perform GI procedures, especially when many patients with COVID-19 have gastrointestinal (GI) symptoms.
Surveillance recommendations are based on the initial grade of dysplasia.
Researchers evaluated the efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders, in patients with moderate to severe ulcerative colitis.
The absolute 1-year risk of colorectal cancer in patients with atrial fibrillation treated with oral anticoagulants is not trivial.
Although patients with COVID-19 are known to present with constitutional and respiratory symptoms such as fever, cough, sore throat, and shortness of breath, there is growing evidence that these patients can also experience significant gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
The American Gastroenterological Association recently published new clinical practice guidelines on the management of gastric intestinal metaplasia.
A commonly used over-the-counter treatment for IBS is peppermint oil. The exact mechanism of action in IBS is not entirely known; however, it has been postulated that it may be mediated through smooth muscle relaxation, antimicrobial effects, modulation of pain receptors, and 5-hydroxytryptamine antagonism.
Esophageal squamous cell carcinoma represents the predominant histologic type of esophageal cancer worldwide.